Health ❯ Healthcare ❯ Obesity

Weight Loss

Medications Pharmaceuticals GLP-1 Drugs Mounjaro Weight Loss Drugs Weight Loss Injections GLP-1 Medications Bariatric Surgery Medication Tirzepatide Clinical Trials Prescription Drugs Interventions Clinical Studies Surgical Methods Incretin Drugs Market Trends Orforglipron GLP-1 Agonists Weight-Loss Surgery Metabolic Health Medication Accessibility Patient Outcomes GLP-1 Treatments Zepbound Medication for Weight Loss Weight-loss Injections Patient Care Injectable Medications Long-term Effects GLP-1 Pill Obesity Drugs GLP-1 Receptor Agonists Semaglutide Behavioral Change Generic Medications Cancer Risk Reduction

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

Lilly aims to seek approval with a potential 2026 rollout, positioning the once‑daily tablet as a more accessible alternative to injections.

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss